Rhinoconjunctivitis Clinical Trial
Official title:
An Optional 1 Year Follow up Study to Evaluate the Continued Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with
allergic rhinoconjunctivitis and/or asthma.
The purpose of this optional observational follow-on study is to further evaluate
rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who
completed all dosing visits in study CP005 approximately one year after the start of
treatment.
Subjects who completed all dosing visits and the post treatment challenge (PTC) in study CP005 will be invited to attend the Screening Visit for CP005A. Subjects will attend for 4 visits to the EEC on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later. ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
Completed |
NCT02849210 -
A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea
|
Phase 1 | |
Completed |
NCT02150343 -
Phase II HDM-SPIRE Safety and Efficacy Study
|
Phase 2 | |
Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
Completed |
NCT01949428 -
House Dust Mite Observational Study
|
N/A | |
Completed |
NCT01949415 -
An Optional Investigation of Biomarkers of Efficacy
|
N/A | |
Completed |
NCT01949441 -
ToleroMune House Dust Mite (HDM) Tolerability Study
|
Phase 2 | |
Completed |
NCT01447784 -
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
|
Phase 2 | |
Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Completed |
NCT01720251 -
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
|
Phase 2 | |
Completed |
NCT01620762 -
Phase III Cat-PAD Study
|
Phase 3 | |
Completed |
NCT01448603 -
ToleroMune Ragweed Follow up Study
|
N/A | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
Completed |
NCT00540631 -
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
|
Phase 3 | |
Completed |
NCT00537342 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
|
Phase 3 | |
Completed |
NCT05540717 -
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
|
Phase 3 | |
Completed |
NCT02844842 -
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
|